Evidence-based guide to tirzepatide (Mounjaro) dosing in young adults aged 18 to 29, covering escalation schedules, clinical trial data, fertility considerations, and practical tips for this age group.
Evidence-based monitoring guide for young adults aged 18 to 29 on Mounjaro (tirzepatide), covering labs, fertility considerations, mental health screening, and dose-titration safety checks.
Evidence-based NMN and NR (nicotinamide mononucleotide and nicotinamide riboside) dosing protocols for adults aged 30 to 49, including clinical trial doses, safety data, and optimization strategies.
A guide to monitoring NMN and NR supplementation in adults aged 30 to 49, including baseline labs, follow-up intervals, NAD+ biomarkers, liver and kidney panels, and when to adjust dosing.
Find out whether Blue Cross Blue Shield (Federated) covers NMN or NR supplements, what formulary tier applies, prior authorization requirements, and how to appeal a denial.
Full drug-drug interaction profile for nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR), including NAD+ pathway conflicts, chemotherapy concerns, and monitoring guidance.
A clinical review of nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR) pipeline formulations, novel delivery systems, combination strategies, and upcoming trials shaping NAD+ precursor therapy.
Evidence-based guide to NMN and NR dosing for adults 65 and older, covering safe starting doses, renal considerations, drug interactions, and clinical trial data on NAD precursors in geriatric populations.
Evidence-based guide to nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR) dosing in patients with liver disease, including NAD+ metabolism changes, safety data, and clinical considerations.
Kaiser Permanente does not cover NMN or NR supplements. Learn why NAD+ precursors fall outside formulary coverage, what they cost out of pocket, and how the regulatory landscape may change.
A clinical guide to nicotinamide mononucleotide and nicotinamide riboside manufacturing processes, global supply chain disruptions, FDA regulatory actions, and current availability for NAD precursor supplementation.
A clinical review of the nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR) patent positions, FDA regulatory status, and projected generic availability timelines.
Genetic variants in NAMPT, NMNAT, CD38, and PARP enzymes alter how your body converts NMN and NR into NAD+. Learn which polymorphisms matter and what the clinical data shows.
A clinical breakdown of nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR) pharmacokinetics, including oral bioavailability, tissue distribution, NAD+ biosynthesis pathways, and elimination half-life data from human trials.
A physician-level review of real-world evidence for nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR), including registry data, observational cohorts, and how RWE compares to RCT findings on NAD+ precursors.
Evidence-based guide to switching between nicotinamide mononucleotide (NMN), nicotinamide riboside (NR), and other NAD+ precursors, including dosing protocols, pharmacokinetic differences, and clinical considerations.
No RCTs have tested NMN or NR in adults under 30. Trial doses of 250-1,000 mg were studied in ages 40-75, not younger adults. See what the evidence actually shows.
Is NMN or NR safe for adults aged 18-29? Review of clinical trial data, dose ceilings, NAD+ biology, and what young adults should know before supplementing with nicotinamide mononucleotide or nicotinamide riboside.
A clinical review of BPC-157 pentadecapeptide for gastrointestinal healing, covering preclinical evidence, proposed mechanisms, dosing practices, safety considerations, and FDA regulatory status.
Evidence-based guide to off-label CJC-1295 (modified GRF 1-29) use for recovery, including clinical data, dosing protocols, monitoring requirements, and safety considerations.
Enclomiphene raises testosterone and LH/FSH and preserves sperm production, but no trial has yet proven it improves live birth rates. See the evidence and tradeoffs.
Enclomiphene citrate is used off-label for gynecomastia by raising endogenous testosterone and correcting the estrogen-to-androgen ratio. Learn the evidence, dosing protocols, and monitoring requirements.
Can enclomiphene citrate treat gynecomastia? We review the pharmacology, off-label evidence, dosing protocols, risks, and how it compares to tamoxifen and raloxifene for male breast tissue reduction.
A clinical evidence summary of oral estradiol's off-label use for cognitive decline prevention, including key trials like WHIMS, KEEPS-Cog, and ELITE, the critical window hypothesis, and current guideline positions.
Evidence-based guide to using oral estradiol off-label for osteoporosis prevention and treatment, including dosing considerations, clinical trial context, and a clinician-discussion and monitoring framework.
Oral estradiol is used off-label for osteoporosis prevention and treatment. Learn the evidence behind this use, required monitoring protocols, and how it compares to FDA-approved therapies.
Oral estradiol is widely used off-label for feminizing hormone therapy in transgender women. This guide covers dosing, VTE risk, cardiovascular tradeoffs, and how oral compares to transdermal routes.
A clinical evidence summary on using transdermal estradiol patches off-label for perimenopausal mood disturbances, including trial data, dosing, and guideline positions.
A clinical review of finasteride's off-label use in gender-affirming hormone therapy, including evidence quality, dosing patterns, and safety considerations for transgender patients.
Finasteride is used off-label for hirsutism in women at 2.5 to 5 mg/day. Learn the dosing protocol, trial evidence, contraindications, and how it compares to spironolactone.
A clinical evidence summary of off-label finasteride use for hirsutism, including trial data, dosing protocols, safety concerns, and how it compares to spironolactone and flutamide.
A clinical evidence review of copper tripeptide GHK-Cu for skin regeneration, covering mechanism of action, trial data, dosing protocols, safety, and off-label status.
A clinical evidence summary of copper tripeptide GHK-Cu for wound healing, including trial data, mechanism of action, dosing protocols, and off-label status.
Inclisiran cuts LDL-C ~50%, but ORION-4 shows only modest event reduction versus PCSK9 antibodies. See dosing, mechanism, and guideline status.
Is metformin effective for cancer prevention? We review the clinical evidence, dosing protocols, and limitations of off-label metformin use for reducing cancer risk.
A analysis of metformin's off-label use for cancer prevention, including trial data, proposed mechanisms, risk-benefit tradeoffs, and who might benefit most.
A clinical evidence summary of off-label metformin use for weight maintenance, including trial data from the DPP/DPPOS, dosing guidance, and how it compares to newer GLP-1 therapies.
Tirzepatide (Mounjaro) is not FDA-approved for heart failure, but emerging trial data suggest cardiovascular benefits in patients with HFpEF and obesity. Here is what clinicians and patients need to know about off-label use, risks, and tradeoffs.
Tirzepatide (Mounjaro) is not FDA-approved for sleep apnea, but clinical trial data from SURMOUNT-OSA show significant AHI reductions. Here's what the evidence actually says about off-label use, risks, and who might benefit.
Off-label dosing is 200 mg twice daily or 400 mg at bedtime, with moderate evidence supporting outcomes similar to vaginal progesterone in IVF.
A clinical review of using semaglutide (Ozempic 0.5-2.0 mg) off-label for heart failure, including trial data, safety signals, and how it compares to FDA-approved HFpEF therapies.
A clinical review of semaglutide (Ozempic) for kidney protection, including FLOW trial data, off-label considerations, dosing, risks, and what the evidence actually supports.
Clinical evidence review of off-label semaglutide (Ozempic 0.5-2.0 mg) for nonalcoholic steatohepatitis (NASH), including trial data, dosing, and guideline positioning.
A clinical evidence summary of off-label semaglutide (Ozempic 0.5 to 2.0 mg) for weight loss, including trial data, FDA status, dosing, and how it compares to on-label Wegovy.
Ozempic (semaglutide 0.25-2.0 mg) is FDA-approved for type 2 diabetes but widely prescribed off-label for weight loss. Learn the evidence, proper monitoring, and clinical protocols.
A clinical evidence summary of bremelanotide (PT-141) for female sexual dysfunction, including trial data, FDA-approved indications, off-label considerations, dosing, and safety profile.
How to monitor patients using PT-141 (bremelanotide) for female sexual dysfunction, including blood pressure checks, nausea management, skin assessments, and cardiovascular screening before and during treatment.
Can liraglutide 3 mg (Saxenda) treat alcohol use disorder? We review the preclinical and early clinical evidence, FDA-approved indications, risks, and what patients should know about this off-label use.
A clinical review of liraglutide 3 mg (Saxenda) used off-label for polycystic ovary syndrome (PCOS), covering trial data, metabolic and reproductive outcomes, side effects, and when prescribers consider it.
Sermorelin acetate is used off-label for adult growth hormone deficiency (GHD). This guide covers dosing protocols, clinical evidence, FDA status, and monitoring requirements.
TB-500 (thymosin beta-4 active fragment) is used off-label for muscle recovery. Review the preclinical evidence, reported dosing protocols, safety signals, and FDA status before considering this peptide.
TB-500 (thymosin beta-4 active fragment) is used off-label for muscle recovery. Review the preclinical evidence, monitoring requirements, dosing protocols, and safety considerations.
Testosterone cypionate is used off-label for frailty syndrome in older men with low testosterone. Review the clinical trial evidence, risks, dosing considerations, and what guidelines recommend.
What baseline and follow-up labs are actually needed for off-label testosterone cypionate in gender-affirming hormone therapy, with a monitoring decision framework and clear notes on where the evidence is thin.
A clinical evidence summary on using testosterone cypionate off-label for sarcopenia, including trial data, dosing considerations, guideline positions, and safety monitoring.
A clinical review of testosterone cypionate as an off-label treatment for sarcopenia, covering trial data, dosing considerations, cardiovascular risks, and guideline recommendations.
A clinical review of semaglutide 2.4 mg (Wegovy) used off-label for binge eating disorder, including dosing protocols, trial evidence, safety data, and what patients should discuss with their provider.
Semaglutide 2.4 mg (Wegovy) reduces major cardiovascular events by 20% in the SELECT trial. Learn when CV prevention use is on-label vs. off-label, the dosing protocol, evidence grade, and what clinicians should consider.
FDA approved Wegovy in March 2024 to cut cardiovascular risk in adults with heart disease and obesity, after SELECT trial showed a 20% MACE reduction.
Semaglutide 2.4 mg (Wegovy) is not FDA-approved for NASH. Here is what the phase 2 trial data shows about NASH resolution, the risks of off-label use, and how clinicians weigh the tradeoffs.